We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-2.88%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$123M
AUM Growth
-$7.76M
Cap. Flow
+$2.93M
Cap. Flow %
2.38%
Top 10 Hldgs %
99.58%
Holding
12
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$5.14M

Top Sells

Rank Stock Value
1
TARA icon
Protara Therapeutics
TARA
+$1.98M
2
PVLA
Palvella Therapeutics
PVLA
+$235K

Sector Composition

Rank Sector Weight
1 Healthcare 80.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
1
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$40M 32.5%
2,600,410
– –
JUNO
2
DELISTED
Juno Therapeutics, Inc.
JUNO
$23.2M 18.81%
1,229,512
– –
EGLT
3
DELISTED
Egalet Corporation
EGLT
$22.1M 17.94%
2,889,926
– –
KYNB
4
Kyntra Bio
KYNB
$28.5M
$17.6M 14.28%
32,887
– –
NBRV
5
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$6.83M 5.54%
4,584
– –
CDTX
6
DELISTED
Cidara Therapeutics
CDTX
$5.15M 4.18%
+24,753
New +$5.14M
EPIX
7
DELISTED
ESSA Pharma
EPIX
$3.72M 3.02%
84,848
– –
PVLA
8
Palvella Therapeutics
PVLA
$1.98B
$2.38M 1.93%
21,217
-1,895
-8% -$235K
EDIT icon
9
Editas Medicine
EDIT
$399M
$1.07M 0.87%
66,162
– –
DRNA
10
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$644K 0.52%
223,457
– –
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$522K 0.42%
301,477
– –
TARA icon
12
Protara Therapeutics
TARA
$226M
– –
-6,250
Closed -$1.98M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q4 2016 Portfolio in Review

As of Q4 2016, Omega Fund Management held 12 positions worth $123M, down 5.9% from $131M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Omega Fund Management's Q4 2016 filing shows 1 new, 1 reduced and 1 closed positions. Its largest new stake was Cidara Therapeutics: 24,753 shares worth $5.15M. The largest sale was Protara Therapeutics, an estimated $1.98M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 71% a quarter earlier.

  • Omega Fund Management's largest Q4 2016 buy was Cidara Therapeutics: 24,753 shares worth $5.15M.
  • Omega Fund Management's biggest Q4 2016 reduction was Palvella Therapeutics, cutting an estimated $235K.
  • Omega Fund Management fully exited Protara Therapeutics in Q4 2016, selling an estimated $1.98M.
  • Omega Fund Management's ten largest holdings make up 100% of its $123M portfolio in Q4 2016.
  • Omega Fund Management opened 1 new position and closed 1 in Q4 2016.
  • Omega Fund Management's portfolio value fell 5.9% quarter-over-quarter to $123M.

Based on Omega Fund Management's 13F filing for Q4 2016, filed 10 Feb 2017.